Company / Current Liabilities
Arbutus Biopharma Corp Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$6.0M
FY2025
5-year range
$6.0M / $32.9M
FY2021-FY2025
Trend
-61.5%
vs FY2024
Sector context
#210 of 213
Health Care
What the data says
Among 213 Health Care companies, Arbutus Biopharma Corp is in the top 1% for current liabilities. Current Liabilities has declined for 3 consecutive years, from $33M in FY2022 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -8.8%.
Improved from $22M to $6M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -43.2%
- 5-Year CAGR
- -8.8%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 213This company $6.0M Sector average $1.6B
▼
-99.6% below sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's current liabilities has declined for 3 consecutive years.
- 5-year CAGR of -8.8%, indicating a declining trend.
- In FY2025, current liabilities decreased 61.5% year-over-year.
- Ranks #210 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.0M | -61.5% |
| FY2024 | $15.6M | -30.5% |
| FY2023 | $22.5M | -31.6% |
| FY2022 | $32.9M | +192.8% |
| FY2021 | $11.2M | +17.6% |
| FY2020 | $9.5M | +21.9% |
| FY2019 | $7.8M | -30.3% |
| FY2018 | $11.2M | -23.2% |
| FY2017 | $14.6M | +38.2% |
| FY2016 | $10.6M | +0.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026